naj-sharif
Editor in Chief
Naj Sharif, PhD, FARVO, FBPhS
Executive Director Santen Inc

Adjunct Professor, University of North Texas
and, Texas Southern University.
phone: (415)-268-9181
E-mail: najam.sharif@santen.com


Education

Degree Field of Study Institution and Location
Ph.D Neuroscience Southampton University; England, UK
BSc Joint Honors in Physiology & Biochemistry Southampton University; England, UK

Biography

Dr. Naj Sharif is a graduate of Southampton University, England (UK) where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). Dr. Sharif has been in the pharmaceutical industry for >30-years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Executive Director, R&D Division). Dr. Sharif’s 23-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Emedine®, Simbrinza®, Izba® and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies. He was recently co-responsible for acquiring Innfocus Inc for Santen, and has thus helped add a device for glaucoma treatment to the product pipeline of Santen. He was recently elected as a Fellow of ARVO (FARVO), and Fellow of British Pharmacology/Pharmaceutical Society (FBPhS) for his exemplary service on numerous committees, progress on drug discovery, and advancement of scientific reputation of both societies. He was honored as the first recipient of the inaugural Dr. Roger Vogel award for pharmaceutical research presented by the ARVO Foundation (2014), and he just received the “Sir James Black Award” for contributions to drug discovery from BPS (2017). He has been an organizer, chairman and invited Keynote speaker at numerous global conferences, symposia and workshops. Dr. Sharif serves on the editorial boards of numerous scientific journals, is an adjunct Professor at several universities, and a thesis advisor for MS- and PhD-level students. He has published >190 scientific articles and edited 2 Neuroscience books. Dr. Sharif is also the holder of >22 issued US and EU patents on ocular cell-lines and small molecules to treat human diseases of the CNS and the eye. He has interests in discovering, developing and bringing to the market novel drugs (including neuroprotectants) / devices / diagnostic therapeutics to alleviate the symptoms and suffering associated with human ocular and CNS diseases.

Research Interest

  • Discovering, developing and bringing to the market novel drugs (including neuroprotectants) / devices / diagnostic therapeutics to alleviate the symptoms and suffering associated with human ocular and CNS diseases.

Scientific Activities

Honors and Awards

2011-present Adjunct Professor & Graduate Faculty @ Texas Southern University (School of Pharmacy, Houston
2012-present Associate Editor: J Ocular Pharmacology & Therapeutics
2012-present Associate Editor: Medical Hypothesis, Discovery & Innovation Ophthalmology
1996-present J Ocular Pharmacology & Therapeutics
2011- present Molecular Vision
2012-present European J Pharmacology
2011-present Current Eye Research
2011-present J Autocoids and Hormones
2013-present Int. J. Ophthalmology
2012-present World J Ophthalmology
2016-present Austin J Pharmacology & Therapeutics
2017 Invited speaker at GTCBio Conference on “Ocular Diseases Drug Discovery”San Diego. Title of my presentation: “Novel Glaucoma Treatment Options”.
2017 Co-Organizer and session Moderator for ARVO Workshop titled “Novel models and trends for accelerating applied ophthalmic product discovery and development” for the Commercial Relations Committee.
2017 Organizing Committee member and Invited Speaker at 2nd Annual Summit on Ophthalmic Drug Development in Boston,Title of my presentation: “Drugs and Devices as Weapons against Glaucoma”.
2017 Organizing Committee member and Invited Speaker at Targeting Ocular Disorders conference, Boston,Title of my talk: “Novel Glaucoma Drugs and Devices: Paving the Paths Towards Retinoprotection”.
2017 Recipient of the “Sir James Black Award” for contributions to drug discovery (BPS,).
1994 to 2017 Adjunct Professor at University of N. Texas (Dept. Pharmacology & Neuroscience
2016 Chairman and Moderator of 2 Mini-Symposia at ARVO 2015. “Role of miRNAs in Ocular physiology & disease”; and “Gaseo-transmitters in ocular physiology & disease”.
2016 Moderator and Judge for “Members in Training (MIT)” posters for the Physiology & Pharmacology (PH) section of ARVO (Seattle).
2016 Elected to serve on the “Commercial Relations Committee” of ARVO .
2016 Chairman and Keynote Speaker at “Ophthalmic Drug Development Summit” conference. My Keynote address: “Innovative Approaches & Alliances Addressing Unmet Medical Needs to Treat Ocular Diseases”.
2016 Chairman of the “Targeting Ocular Disorders” conferences
2016 Organizer and speaker at ISER 2016 “Prostaglandins for Ocular Hypertension Treatment: A new Era is Dawning”. Titles of my presentations: “Introduction to Prostaglandins and their Receptors in the Eye” and “EP2 Receptor Agonists as Novel Drugs to treat OHT and Glaucoma”.
2016 Elected as Fellow of British Pharmacological/ Pharmaceutical Society (BPS) (FBPhS,
2016 Invited Keynote speaker and Guest of Honor @ “10th Int. Conference on Clinical & Experimental Ophthalmology”. Title of my presentation: “Glaucoma Treatment: Novel Drugs and Devices on the Horizon”.
2015 Elected as Fellow of ARVO (FARVO) and presented the Silver Medal .
2012-2015 Elected to ARVO’s Annual Meeting Program Committee (AMPC) for Physiology/Pharmacology section to serve for three years.
2012-2015 Volunteered to serve on ARVO’s initiative to provide “Best Practices for Submitting Successful Abstracts” for annual conference meetings of ARVO. Formulated optimum “Guidelines for Authors”. (Served on Task Force along with 3 other volunteers [Mary Elizabeth Hartnett; Gadi Wollstein; Lorraine Birks]:
2015. Keynote speaker at “Targeting Ocular Disorders” conference, Boston. My presentation title: “New Horizons for Glaucoma / OHT Therapy- Techniques, Technologies & Promising Therapeutics”.
2014 Mini-Symposium organizer and speaker on “Changes in Cell Volume Effecting IOP”, ARVO 2014 (Orlando).
2014 Awarded the 1st and inaugural “Dr. Roger Vogel Award” for Pharmaceutical Research (awarded at ARVO.
2011-2014 Int. Drug Discovery
2012-2013 Editor-in-Chief: Current Molecular Pharmacology
2009-2013 J Ophthalmology
2009-2013 Int J Hypertension
2008-2013 Current Molecular Pharmacology
2013 Mini-Symposium organizer and speaker on “Peptides and Polypeptides in Ocular Health and Dysfunction”, ARVO  (Seattle, WA).
2010-2011 PLos ONE
2009-2012 Elected to ARVO Diversity Initiative Committee (served during)
2011-2012 Bio-graphed in “Marquis Who’s Who in Medicine & Healthcare”.
July 2010 Invited Organizer and invited speaker for ISER 2010 (Montreal, Canada); symposium on “Enzyme inhibitors/ activators & gaseous transmitters: role in ocular hypertension treatment.”
2005 – 2010 Member of the Alcon Corporate Patents Committee. A select team of 15 senior managers from Alcon across the world (many based at Alcon HQs in TX).
2005-2008 Adjunct Professor at University of Houston (School of Pharmacy
2008 Invited speaker at Mini-Symposium on: My talk: “The Many Diverse Roles of Serotonin in Ocular Biology”. ARVO (Fort Lauderdale).
2008 Invited speaker for ISER’08 (Beijing, China); Symposium on “The Many Diverse Roles of Serotonin in Ocular Biology”. My lecture title: “Serotonin-2 receptor agonists as novel efficacious ocular hypotensive agents”.
2008-2009 Corporate Advisory Board (CAB) member at University of Houston, School of Pharmacy & Pharmacology
2007 Invited speaker at Uni’ Texas, Arlington. Lecture to graduate students; title: “Life and Work in the Pharmaceutical Industry”. Invited by Uni’ President (Dr. Greg Hale).
2006 Invited speaker and Symposium Organizer for ISER 2006 (Buenos Aires, Argentina).
1990 - 2005 Neurochemical Research
2004 Invited speaker in Symposium on Ocular Drug Discovery & Development at the Int. Congress of Eye Research (ISER), Sydney Australia.
2003 Invited speaker in Symposium on “Cell Fate: Signaling from Proliferation to Apoptosis”. ARVO, Ft. Lauderdale.
2003 Co-chair Oral presentations session on “Receptors & Second Messengers”, ARVO, Ft. Lauderdale.
2002 Invited speaker in symposium on “Fluorescence Technologies for study of Receptors” at the XIVth World Congress of Pharmacology (IUPHAR). San Francisco, July.
1999-2000 Adjunct Professor & Graduate Faculty @ Creighton University (School of Pharmacy, Omaha

Publications

  1. Roberts PJ , Sharif NA. Effects of L-glutamate and related amino acids upon the release of [3H]-dopamine from rat striatal slices. Brain Research, 157, 391-394 (1978). (paper resulting from an under-graduate research project)
  2. Sharif NA, Roberts PJ. Problems associated with binding of L-glutamic acid to synaptic membranes - methodological aspects. Journal of Neurochemistry, 34, 779-784 (1980).
  3. Sharif NA, Roberts PJ. Effects of guanine nucleotides on binding of [3H]-glutamate to cerebellar synaptic membranes. European J. Pharmacology, 61, 213-214 (1980).
  4. Sharif NA , Roberts PJ. Effects of protein and membrane modifying agents on the binding of [3H]-glutamate to cerebellar membranes. Brain Research, 194, 594-597 (1980).
  5. Sharif NA, Roberts PJ. Cerebellar glutamate receptors: Studies on their stability, susceptibility to protein and membrane modifying agents and effects of guanine nucleotides. In: Neurotransmitters and Their Receptors. UZ Litauer et al. (Eds). John Wiley & Sons, London, pp. 369-372, (1980).
  6. Sharif NA, Roberts PJ. L-aspartate binding sites in rat cerebellum: comparison of [3H]-aspartate and [3H]glutamate binding to synaptic membranes. Brain Research, 211, 293-303 (1981).
  7. Roberts PJ, McBean GJ, Sharif NA, Thomas, EM. Striatal glutamatergic function: modification following specific lesions. Brain Research, 235, 83-91 (1981).
  8. Sharif NA , Roberts PJ. Regulation of cerebellar [3H]-glutamate binding: influence of guanine nucleotides and Na+ ions. Biochemical Pharmacology, 30, 3019-3022 (1981).
  9. Roberts PJ, Sharif NA. Radioreceptor binding studies with glutamate and aspartate. In: Glutamate as a Neurotransmitter. Vol. 27, Advances in Biochemical Pharmacology, G. di Chiara & GL.Gessa (Eds), Raven Press, New York, pp. 298-305 (1981).
  10. Roberts PJ, Foster GA, Sharif NA, Collins JF. Phosphonate analogs of acidic amino acids: inhibition of excitatory amino acid binding to cerebellar membranes and of the stimulation of cerebellar cyclic GMP levels. Brain Research, 238, 475-479 (1982).
  11. Sharif NA, Burt DR, Towle AC, Mueller RA, Breese GR. Codepletion of serotonin and TRH induces apparent supersensitivity of spinal TRH receptors. European J. Pharmacology, 95, 301-304 (1983).
  12. Sharif NA, Burt DR. Receptors for thyrotropin-releasing hormone (TRH) in the rabbit spinal cord. Brain Research, 270, 259-263 (1983).
  13. Sharif NA, Burt DR. Biochemical similarity of rat pituitary and CNS TRH receptors. Neuroscience Letters., 39, 57-63 (1983).
  14. Sharif NA, Zuhowski EG , Burt DR. Benzodiazepines inhibit TRH receptor binding - micromolar potency in retina, amygdala and pituitary. Neuroscience Letters., 41, 301-306 (1983).
  15. Sharif NA, Pilotte, NS & Burt, DR. Biochemical and autoradiographic studies of TRH receptors in sections of rabbit spinal cord. Biochemical Biophysical Research Communications, 116, 669-674 (1983).
  16. Sharif NA , Burt DR. Rat brain TRH receptors: kinetics, pharmacology, distribution and ionic effects. Regulatory Peptides., 7, 399-411 (1983).
  17. Sharif NA, Burt DR. Micromolar substance P reduces spinal TRH receptor binding-possible relevance to neuropeptide coexistence? Neuroscience Letters., 43, 245-251 (1983).
  18. Pilotte N, Sharif NA, Burt DR. Characterization and autoradiographic localization of TRH receptors in sections of rat brain. Brain Research, 293, 372-376 (1984).
  19. Sharif NA. Apparent super high-affinity recognition sites in rat cortical membranes: allosteric sites for peptides? IRCS. Medical Science, 12, 1038-1039 (1984).
  20. Sharif NA , Burt DR. Sulphydryl groups in receptor binding of thyrotropin releasing hormone to rat amygdala. Journal of Neurochemistry, 42, 209-214 (1984).
  21. Sharif NA, Burt DR. Modulation of receptors for thyrotropin releasing hormone by benzodiazepines: brain regional differences. Journal of Neurochemistry, 43, 742-746 (1984).
  22. Sharif NA, Roberts PJ. Neurochemical, pharmacological and developmental studies on cerebellar receptors for dicarboxylic amino acids. Neurochemical Research, 9, 81-102 (1984).
  23. Sharif NA. Excitatory Amino Acid Receptors. In: Handbook of Neurochemistry, Vol. 6, (A. Lajtha, Ed), Chapter 9, pp.239-250, Plenum Press, New York (1984).
  24. Burt DR, Sharif NA, Peptide Receptors. In: Handbook of Neurochemistry, Vol. 6 (A. Lajtha, Ed), Chapter 13, pp. 353-378, Plenum Press, New York (1984).
  25. Sharif NA. Comparative autoradiographic visualization of muscarinic, benzodiazepine and TRH receptors in mammalian spinal cord slices. IRCS. Medical Science, 12, 1016-1017 (1984).
  26. Sharif NA, Burt DR. Visualization and identification of TRH receptors in rodent brain by autoradiography and radioreceptor assays: focus on amygdala, nucleus accumbens, septum and cortex. Neurochemistry International, 7, 525-532 (1985).
  27. Sharif NA. Serotonin1 (5HT1) receptors modulate striatal dopaminergic transmission: studies on uptake, release and receptor mechanisms. IRCS. Medical Sciences, 13, 368-369 (1985).
  28. Sharif NA, Burt DR. Limbic, hypothalamic, cortical and spinal regions are enriched in receptors for TRH: evidence from [3H]-Ultrofilm autoradiography and correlation with central effects of the tripeptide in rat brain. Neuroscience Letters., 60, 337-342 (1985).
  29. Sharif NA. Diverse roles of thyrotropin-releasing hormone in brain, pituitary and spinal cord function. Trends Pharmacological Sciences (TIPs) 6, 119-122 (1985).
  30. Sharif NA. Support for analeptic action of thyroliberin (TRH) - apparent induction of limbic forebrain TRH receptors after ethanol treatment. IRCS. Medical Sciences., 13, 60-61 (1985).
  31. Sharif NA. Multiple synaptic receptors for neuroactive amino acid transmitters-new vistas. International Reviews in Neurobiology 26, 85-150 (1985).
  32.  Sharif NA, White WF, Burt, DR . Properties & distribution of TRH receptors in normal & spastic mutant mouse brain & spinal cord. Neurochemistry International 11, 63-68 (1987).
  33. Sharif NA. Adaptive changes in brain and pituitary TRH receptors: effects of lesions, kindling, hormones, drugs and other factors. Medical Science Research. 15, 223-227 (1987).
  34. Sharif NA, Burt DR. Guanine nucleotide regulation of receptors for TRH in rat brain regions and pituitary. Neuroscience Letters., 81, 339-344 (1987).
  35. Sharif NA. Effects of some peptidase inhibitors on TRH-receptor interactions in rat amygdala homogenates. Medical Science Research, 16, 219-220 (1988).
  36. Sharif NA, Whiting RL. [125I]-conotoxin labels picomolar spinal and brain N-type Ca2+-channels: modulation by cations and endothelin. Medical Science Research, 16, 1183-1184 (1988).
  37. Clark CR, Birchmore B, Sharif NA, Hunter JC, Hill RG, Horwell D, Hughes J. PD117302: a new kappa-selective opioid agonist. British J. Pharmacology, 93, 618-626 (1988).
  38. Sharif NA. Chronic prolactin, gonadal and thyroid hormone treatments in vivo alter levels of TRH and muscarinic receptors in male and female rat tissues. Brain Research, 449, 364-368 (1988).
  39. Sharif NA. Chemical and surgical lesions of the rat olfactory bulb: changes in thyrotropin-releasing hormone and other systems. Journal of Neurochemistry, 50, 388-394 (1988).
  40. Sharif NA, Hunter JC, Hill RG, Hughes, J. Bradykinin-induced accumulation of [3H]inositol-1-phosphate in human embryonic pituitary tumor cells by activation of a B2-receptor. Neuroscience Letters., 86, 279-283 (1988).
  41. Sharif NA, Michel AD, Whiting RL. Affinities of bradykinin (BK) analogs and identification of B2 bradykinin receptors in guinea pig brain, spinal cord and peripheral tissues using [3H]-BK binding. Medical Science Research, 16, 1235-1236 (1988).
  42. Tones M, Sharif NA, Hawthorne JN. Phospholipid turnover during cell-cycle traverse in synchronous Chinese-Hamster ovary cells. Biochemical Journal, 249, 51-56 (1988).
  43. Sharif NA, Hunter JC, Hill RG, Hughes, J. [125I]-dynorphin (1-8) produces a similar pattern of kappa opioid receptor labelling to [3H]-dynorphin (1-8) and [3H]-etorphine in guinea pig brain: a quantitative autoradiographic study. Neuroscience Letters., 86, 272-278 (1988).
  44. Sharif NA, Hughes J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides, 10, 499-522 (1989).
  45. Sharif NA. Quantitative autoradiography of TRH receptors in discrete brain regions of different mammalian species. Annals New York Academy of Sciences, 553, 147-175 (1989).
  46. Eglen RM, Michel AD, Sharif NA, Swank S, Whiting RL. Pharmacological properties of the peptide, endothelin. British J. Pharmacology, 97, 1297-1307 (1989).
  47. Sharif NA, Nunes JL, Michel AD, Whiting RL. Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [3H]-GBR12935 binding and [3H]dopamine uptake. Neurochemistry International 15, 325-332 (1989).
  48. Sharif NA, To Z, Michel, AD, Whiting, RL. Differential affinities of TRH analogs at the mammalian spinal cord TRH receptor: implications for therapy in spinal injuries. Neuroscience Letters. 104, 183-188 (1989).
  49. Sharif NA, Hughes J. Neuroanatomical mapping and quantification of peptide and drug receptors by quantitative digital subtraction autoradiography. In: Brain Imaging: Techniques and Applications. (Sharif NA, Lewis ME; Eds). Ellis Horwood Ltd, Chichester, pp. 36-76 (1989).
  50. Sharif NA, Towle AC, Burt DR, Mueller RA, Breese GR. Co-transmitters: differential effects of serotonin (5HT)-depleting drugs on 5HT and TRH levels and their receptors in rat brain and spinal cord. Brain Research, 480, 365-371 (1989).
  51. Sharif NA, Michel AD, Whiting RL. Human endothelin stimulates phosphoinositide turnover in murine fibrosarcoma cells. Medical Science Research, 17, 55-56 (1989).
  52. Sharif NA, To Z, Whiting RL. First pharmacological characterization of TRH receptors linked to phosphoinositide hydrolysis in GH3 pituitary cells using agonist specificity of eight TRH analogs. Biochemical Biophysical Research Communications 161, 1306-1311 (1989).
  53. Sharif NA, Michel AD, Whiting RL. [3H]-U69593 and [3H]-etorphine binding suggests the absence of multiple kappa opioid receptors in dog cerebral cortex. Medical Science Research, 17, 213-214 (1989).
  54. Sharif NA. A novel substance P binding site in rat brain regions modulates TRH receptor binding. Neurochemical Research, 15, 1045-1049 (1990).
  55. Burt DR, Sharif NA. TRH receptors. In: Handbook of Chemical Neuroanatomy. (Bjorklund A, Hökfelt T, Kuhar MJ, Eds), Academic Press, Chapter 9, Vol. 9, pp. 477-503, (1990).
  56. Sharif NA, Whiting RL. Stimulation of inositol phosphate production in clonal HSDM1C1 cells by endothelins and sarafotoxin. Biochemical Pharmacology 40, 1928-1931 (1990).
  57. Sharif NA, Durie E, Michel AD, Whiting RL. Dog cerebral cortex contains -, δ- and -opioid receptors at different densities: lack of evidence for sub-types of -receptor using selective radioligands. Brain Research 510, 108-114, (1990).
  58. Sharif NA, Whiting RL. Identification of B2-bradykinin receptors in guinea pig brain regions, spinal cord and peripheral tissues. Neurochemistry International, 18, 89-96 (1991).
  59. Nunes JL, Sharif NA, Michel AD, Whiting RL. Dopamine D2-receptors mediate hypothermia in mice: icv and ip effects of agonists and antagonists. Neurochemical Research 16, 1167-1174 (1991).
  60. Sharif NA, Wong EH, Loury D, Stefanich E, Eglen RM, Michel A, Whiting RL. Characteristics of 5HT3 binding sites in rat cerebral cortex, NG108-15 and NCB-20 neuroblastoma cells using [3H]-quipazine and [3H]-GR65630 binding. British J. Pharmacology, 102, 919-925 (1991).
  61. Ransom J, Cherwinski HM, Delmendo R, Sharif NA , Eglen R. Characterization of m4 muscarinic receptor Ca2+ responses in a subclone of PC-12 cells by single cell flow cytometry. Journal Biological Chemistry, 266, 11738-11745 (1991).
  62. Sharif NA, To ZP, Whiting RL. Analogs of thyrotropin-releasing hormone (TRH): receptor affinities in brains, spinal cords and pituitaries of different species. Neurochemical Research, 16, 95-103 (1991).
  63. Ransom J, Cherwinski HM, Dunne JF, Sharif NA. Flow cytometric analysis of internal calcium mobilization via a B2-bradykinin receptor in a subclone of PC12 cells. Journal of Neurochemistry, 56, 983-989 (1991).
  64. Sharif NA, Nunes JL, Whiting RL. Pharmacological characterization of NMDA-receptor-channel in rodent and dog brain and rat spinal cord using [3H]MK-801 binding. Neurochemical Research, 16, 563-569 (1991).
  65. Ransom JT, Sharif NA, Dunne J, Momiyama M, Melching G. AT-1 angiotensin receptors mobilize intracellular calcium in a subclone of NG108-15 neuroblastoma cells. Journal of Neurochemistry 58, 1883-1888 (1992).
  66. Sharif NA, Nunes JL, Kalfayan V, McLelland DL, Rosenkranz RP, Eglen RM, Whiting RL. Pharmacological comparison of [3H]-GBR12935 binding to rodent striatal and kidney homogenates: binding to dopamine transporters? Neurochemistry International 21, 69-73 (1992).
  67. Sharif NA. TRH Analogs and Receptors. In: Methods in Neuroscience, Chapter 13, Vol. 13, pp.199-219 (Conn PM, Ed.), Academic Press (1993).
  68. Sharif NA, Whiting RL. The neuropeptide bradykinin stimulates phosphoinositide turnover in HSDM1C1 cells: B2-antagonist-sensitive responses and receptor binding studies. Neurochemical Research 12, 1313-1320 (1993).
  69. Kubek MJ, Knoblach SM, Sharif NA, Burt DR, Butterbaugh GG, Fuson KS. TRH gene expression and receptors are differentially modified in limbic foci by seizures. Annals of Neurology 33, 70-76 (1993).
  70. Sharif NA, Eglen RM. Quantitative Autoradiography: A Tool to Visualize and Quantify receptors, Enzymes, Channels and Second Messenger Systems. In: Molecular Imaging in Neuroscience: A Practical Approach, (N.A.Sharif, Ed.), pp. 71-138, Oxford University Press (1993).
  71. Sharif NA, Stevenson DJ. Chinese hamster ovary (CHO-K1) cells: optimum culture conditions, cell-cycle events and phospholipid metabolism in response to serum and calcium ionophore A23187. Medical Science Research 21, 553-556 (1993).
  72. Ransom JR, Dunne JF, Sharif NA. Flow Cytometric selection of responsive subclones and fluorimetric analysis of intracellular calcium mobilization. In: Molecular Imaging in Neuroscience: A Practical Approach. (N.A.Sharif, Ed.), pp.209-233, Oxford University Press (1993).
  73. Eglen RM, Sharif NA, To ZP. Muscarinic M3 receptors mediate total inositol phosphates accumulation in murine HSDM1C1 fibrosarcoma cells. European J. Pharmacology (Mol. Pharmacol.) 244, 49-55 (1993).
  74. Sharif NA, Xu S, Yanni JM. Emedastine (Emedine®): a potent, high affinity histamine H1-selective antagonist for ocular use. Receptor binding and second messenger studies. Journal Ocular Pharmacology 10: 653-664 (1994).
  75. Sharif NA, Xu S, Yanni JM. Histamine receptor-subtype affinities, selectivities and potencies of emedastine (Emedine®), a novel H1-selective antagonist, and other ocularly employed antihistamines. Drug Development Research 33, 448-453 (1994).
  76. Sharif NA, To ZP, Wong KW, Delmendo RE, Whiting RL, Eglen RM. M3 muscarinic receptors on murine HSDM1C1 cells: further functional, regulatory and receptor binding studies. Neurochemical Research 20: 61-68 (1995).
  77. Chidlow G, DeSantis LM, Sharif NA, Osborne NN. The characteristics of [3H]5-hydroxytrytamine binding to iris-ciliary body of the rabbit. Investigative Ophthalmology & Visual Science 36, 2238-2245 (1995).
  78. Blue D, Bonhaus D, Ford APD, Pfister J, Sharif NA, Shieh A, Vimont R, Williams T, Clarke DE. Functional evidence equating the pharmacologically-defined α1A- and cloned α1C-adrenoceptors: studies in the isolated perfused kidney of rat. British J. Pharmacology 115, 283-294 (1995).
  79. Sharif NA, Nunes JL, Rosenkranz, RP, Eglen, RM, Whiting, RL. Quantitative autoradiography demonstrates selective modulation of brain regional dopamine (D1 & D2) receptor subtypes after chronic manipulation of dietary salt. Neurochemical Research 20, 121-128 (1995).
  80. Sharif NA, Williams GW, DeSantis LM. Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]-Oxotremorine (OXO) binding to a mixture of M1-M4 muscarinic receptors: Use of NMS/OXO ratios to group compounds into potential agonist, partial agonist and antagonist classes. Neurochemical Research 20, 669-674 (1995).
  81. Sharif NA, Nunes JL, Lake KD, Rosenkranz RP, McClelland,DL, Corkins,S, Lakatos,I, Whiting, RL, Eglen,RM. Chronic manipulation of dietary salt modulates renal physiology and kidney dopamine receptors: functional and autoradiographic studies. General Pharmacology 26, 727-735 (1995).
  82. Sharif NA Xu S, Magnino P, Pang I-H. Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic & inflammatory diseases. Experimental Eye Research 63, 169-178 (1996).
  83. Sharif NA, Xu S, Yanni JM. Olopatadine (AL-4943A; Patanol®): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist for use in allergic conjunctivitis. Journal Ocular Pharmacology & Therapeutics 12, 401-407 (1996).
  84. Sharif NA, Xu SX. Pharmacological characterization of bradykinin receptors coupled to phosphoinositide turnover in SV40-immortalized human trabecular meshwork cells. Experimental Eye Research 63, 631-637 (1996).
  85. Sharif NA. Quantitative Autoradiographic Methods. In : Brain Mapping - The Methods. (A.Toga & J. Mazziotta, Eds.), Chapter 5, pp. 115-144, Academic Press, New York (1996).
  86. Crider JY, Williams GW, Yorio T, Sharif NA, Griffin BW. A new chromatographic method for rubidium transport activities in cultured bovine retinal pigmented epithelial cells. Ophthalmic Research , 29, 117-123 (1997).
  87. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular anti-allergic and anti-histaminic effects of Olopatadine (AL-4943A; Patanol®), a novel drug for treating ocular allergic diseases. J. Pharmacology & Experimental Therapeutics 278, 1251-1260 (1996).
  88.  BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF. Topical formulations of novel angiostatic steroids (AL-3789; Anecortave acetate) inhibit rabbit corneal neovascularization. Investigative Ophthalmology & Visual Science 38, 1954-1962 (1997).
  89. Sharif NA, Crider JY, Griffin B, Howe W, Davis T. Pharmacological analysis of mast cell mediator and neurotransmitter receptors coupled to adenylate cyclase and phospholipase C on immunocytochemically-defined human conjunctival epithelial cells. J. Ocular Pharmacology & Therapeutics 13, 321-336 (1997).
  90. Griffin BW, Williams GW, Crider JY, Sharif NA. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 Cells: A pharmacological study. J. Pharmacology & Experimental Therapeutics 281, 845-854 (1997).
  91. Wiernas TK, Griffin BW, Sharif NA. The expression of functionally-coupled bradykinin receptors in human corneal epithelial cells and their pharmacological characterization with agonists and antagonists. British J. Pharmacology 121, 649-656 (1997).
  92. Crider JY, Yorio T, Sharif NA, Griffin, BW. The effects of elevated glucose on Na+/K+-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay. Journal Ocular Pharmacology & Therapeutics 13, 337-352 (1997).
  93. Sharif NA, Hellberg MH, Yanni JM. Anti-histamines, topical ocular. In: Burger's Medicinal Chemistry & Drug Discovery, 5th edition, (Wolff MF, ed.), John Wiley & Sons, NY, Chapter 64, Volume 5, pp. 255-279 (1997).
  94. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu SX, Sharif NA. A comparison of topical ocular anti-allergy drugs: effects on human conjunctival mast cell mediator release. Annals Allergy, Asthma & Immunology 79, 541-545 (1997).
  95. Crider JY, Griffin BW, Sharif NA. Prostaglandin-stimulated adenylyl cyclase activity via a pharmacologically-defined EP2 receptor in human NPE cells. J. Ocular Pharmacology & Therapeutics 14, 293-304 (1998).
  96. Sharif NA, Williams GW, Xu SX, Crider JY, Griffin BW, Davis TL. Pharmacological analysis of [3H]PGE1 / [3H]PGE2 and [3H]PGF2 binding in bovine corpus luteum: identification of EP3 and FP prostaglandin receptors and correlation with functional data. J. Pharmacology & Experimental Therapeutics 286, 1094-1102 (1998).
  97. Sharif NA, Wiernas TK, Howe, WL, Griffin, BW, Offord, EA, Pfeifer, AMA. Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Investigative Ophthalmology & Visual Science 39, 2562-2571 (1998).
  98. Wiernas TK, Davis TL, Griffin BW, Sharif NA. Effects of bradykinin on signal transduction, cell proliferation, and cytokine, prostaglandin E2 and collagenase-1 release from human corneal epithelial cells. British J. Pharmacology 123, 1127-1137 (1998).
  99. Griffin BW, Magnino P, Pang I-H, Sharif NA. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J. Pharmacology & Experimental Therapeutics 286, 411-418 (1998).
  100. Sharif NA, Wiernas TK, Griffin BW, Davis TL. Pharmacology of [3H]-pyrilamine binding and the histamine-induced phosphoinositide turnover, Ca2+-mobilization and cytokine release from human corneal epithelial cells. British J. Pharmacology 125, 1336-1344 (1998).
  101. Crider JY, Xu SX, Griffin BW, Sharif NA. Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2- and IP-prostaglandin receptors in human ocular and other cell-types. Prostaglandins, Leukotrienes & Essential Fatty Acids 59, 77-82 (1998).
  102. Sharif NA, Xu SX. Human retina contains polyamine-sensitive [3H]-ifenprodil binding sites: implications for neuroprotection? British J. Ophthalmology 83, 236-240 (1999).
  103. Yanni JM, Weimer L, Sharif NA, Xu SX, Gamache D, Spellman J. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Archives Ophthalmology 117, 643-647 (1999).
  104. Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocular Pharmacology & Therapeutics 15, 323-336 (1999).
  105. Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta. Ophthalmologica Scandinavia 77, 33-37 (1999).
  106. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 (9--[+]fluprostenol): carboxylic acid of Travoprost (AL- 6221), a novel FP-prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharmacy & Pharmacology 51, 685-594 (1999).
  107. Sharif NA , Xu SX. Pharmacological characterization of [3H]-ifenprodil binding to polyamine binding sites on rabbit and rat retinal homogenates: role in neuroprotection? J. Ocular Pharmacol. Therapeutics 15, 271-281 (1999).
  108. Offord E, Sharif NA, Mace K, Tromvoukis Y, Spillare Avanti O E, Howe WL, Pfeifer AMA. Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Investigative Ophthalmology & Visual Science 40, 1091-1101 (1999).
  109. Crider JY, Griffin BW, Sharif NA. Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EbTr) cells: pharmacological characterization using agonists and antagonists. British J. Pharmacology 127, 204-210 (1999).
  110. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel PGF2 analog with selective antagonist effects at the FP prostaglandin receptor. J. Pharmacology & Experimental Therapeutics 290: 1278-1284 (1999).
  111. Sharif NA, Crider JY, Xu SX, Williams GW. Affinities, selectivities, potencies and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J. Pharmacology & Experimental Therapeutics 293: 321-328 (2000).
  112. Davis TL, Sharif NA. Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor. British J. Pharmacology 130: 1919-1926 (2000).
  113. Ohia SE, Opere CA, Awe SO, Adams L, Sharif NA. Human, bovine and rabbit retinal glutamate-induced [3H]D-aspartate release: role in excitotoxicity. Neurochemical Research 25: 853-860 (2000).
  114. Sharif NA, Crider JY, Davis TL. AL-3138 antagonizes FP prostanoid receptor-mediated inositol phosphates generation: comparison with some purported FP antagonists. J. Pharmacy & Pharmacology 52: 1529-1539 (2000).
  115. Sharif NA, Williams GW, Davis TL. Pharmacology and autoradiography of human DP prostanoid receptors using [3H]-BWA868C, a DP receptor-selective antagonist radioligand. British J. Pharmacology 131: 1025-1038 (2000).
  116. Thomas D, Papadopoulo O, Doshi R, Kapin MA, Sharif NA. Retinal ATP and phosphorus metabolites: reduction by hypoxia and recovery with MK-801 and diltiazem. Medical Science Research 28: 87-91 (2000).
  117. Klimko PG, Griffin BG, Davis TL, Sharif NA. Synthesis and biological activity of a novel 11-homo-(cyclohexyl)-prostaglandin. J. Medicinal Chemistry 43: 3400-3407 (2000).
  118. Crider JY, Griffin BW, Sharif NA. Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukotrienes & Fatty Acids 62: 21-26 (2000).
  119. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. J. Pharmacology 432: 211-213 (2001).
  120. Harris LC, Awe SO, Opere CA, LeDay AM, Ohia SE, Sharif NA. [3H]-Serotonin release from bovine iris-ciliary body: pharmacology of pre-junctional serotonin (5HT7) auto-receptors. Experimental Eye Research 73, 59-67 (2001).
  121. Crider JY, Sharif NA. Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J. Ocular Pharmacology & Therapeutics 17: 35-46 (2001)
  122. Hellberg MR, Sallee V, McLaughlin M, Sharif NA, DeSantis L, Dean TR, Zinke PW. Preclinical efficacy of Travoprost (Travatan®), a potent and selective FP prostaglandin receptor agonist. J. Ocular Pharmacology & Therapeutics 17: 421-432 (2001).
  123. Crider JY, Xu SX, Sharif NA. Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins, Leukotrienes & Essential Fatty Acids 65: 253-258 (2001).
  124. Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon) and other –adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocular Pharmacology & Therapeutics 17: 305-317 (2001).
  125. Ohia SE, Awe SO, Opere CA, LeDay AM, Harris LC, Sharif NA. Hypoxia-induced [3H]-D-aspartate release from isolated bovine retina: modulation by calcium channel blockers and glutamatergic agonists and antagonists. Current Eye Research 23: 386-392 (2001).
  126. Sharif NA, Crider JY, Xu SX, McLaughlin M, Davis TL. Levobetaxolol (Betaxon): in vitro pharmacology, intraocular pressure lowering activity and autoradiographic localization of –receptors in human eyes. Proc. Western Pharmacology Society 44: 65-68 (2001).
  127. Rangisetty J, Dukat M, Dowd C, Herrick-Davis K, DuPre A, Gadepalli S, Teitler M, Kelly C, Sharif NA, Glennon R. 1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5HT2A serotonin receptor affinity and antagonist character. J. Medicinal Chemistry 44: 3283-3291 (2001).
  128. Sharif NA, Davis, TL. Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J. Pharmacy & Pharmacology 54: 539-547 (2002).
  129. Hellberg MR, Conrow R. Sharif NA. McLaughlin, M., Bishop, J, Crider, JY, et al. 3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical anti-glaucoma agents. Bioorganic & Medicinal Chemistry 10: 2031-2049 (2002).
  130. Sharif NA, Senchyna M, Xu SX. Pharmacological and molecular biological (RT-PCR) characterization of functional TP prostanoid receptors in immortalized human non-pigmented ciliary epithelial cells. J. Ocular Pharmacology & Therapeutics 18: 141-162 (2002).
  131. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocular Pharmacology & Therapeutics 18: 313-324 (2002).
  132. Harris LC, Awe SO, Opere CA, LeDay AM., Ohia SE, Sharif NA. Pharmacology of serotonin receptors modulating electrically-induced [3H]norepinephrine release from isolated mammalian iris-ciliary bodies. J. Ocular Pharmacology & Therapeutics 18: 339-348 (2002).
  133. Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke, PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry TL, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MVW, Robertson S, Weiner AL, Sallee VL. Identification and characterization of the ocular hypotensive efficacy of Travoprost (Travatan® ), a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Survey of Ophthalmology (Suppl #1), 47: S13-S33 (2002).
  134. Crider JY, Sharif NA. Adenylyl cyclase activity mediated by 2-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J. Ocular Pharmacology & Therapeutics 18: 221-230 (2002).
  135. Kelly CR, Williams GW, Sharif NA. Real-time intracellular Ca2+-mobilization by travoprost acid, bimatoprost, unoprostone and other analogs via endogenous mouse, rat and cloned human FP prostaglandin receptors. J. Pharmacology & Experimental Therapeutics 304: 238-245 (2003).
  136. May JM, Chen H-H, Rusinko A, Lynch, VM, Sharif NA, McLaughlin MA. A novel and selective 5HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1—(2-aminopropyl)-8,9-dihydropyrano-[3,2-e]indole. J. Medicinal Chemsitry 46: 4188-4195 (2003).
  137. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmology & Visual Science 44: 715-721 (2003).
  138. May JM, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5HT1A and 5HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Pharmacology & Experimental Therapeutics 306: 301-309 (2003).
  139. Crider JY, Williams GW, Drace CD, Katoli P, Senchyna M, Sharif NA. Pharmacological characterization of a serotonin receptor (5HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmology & Visual Science 44: 4837-4844 (2003).
  140. Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J. Ocular Pharmacology & Therapeutics 19: 437-455 (2003).
  141. Sharif NA, Kelly CR, Williams GW. Bimatoprost (Lumigan) is an agonist at the cloned human ocular FP receptor: real-time FLIPR-based intracellular Ca2+ mobilization studies. Prostaglandins Leukotrienes & Essential Fatty Acids. 68: 27-33 (2003).
  142. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocular Pharmacology & Therapeutics 19: 501-515 (2003).
  143. Ohia SE, Awe SO, Opere CA, LeDay AM, Harris LC, Kulkarni K, Sharif NA. Glucose deprivation-induced [3H]-D-aspartate release from isolated bovine and human retinae. J. Ocular Pharmacol Therapeutics 19: 599-609 (2003).
  144. Selliah RD, Hellberg MR, Sharif NA, McLaughlin MA, Williams GW, Scott DA, Earnest D. Haggard KS, Dean DW, Delgado P, Gaines, MS, Conrow RE, Klimko PG. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. Biorganic Medicinal Chemistry Letters 14: 4525-4528 (2004).
  145. Sharif NA, Xu SX. Pharmacological characterization and identification of EP3 prostanoid receptor binding sites in hamster uterus homogenates. J. Pharmacy & Pharmacology 56: 197-203 (2004).
  146. Klimko P, Hellberg MR, McLaughlin MA, Sharif NA, Severns B, Williams GW, Haggard KS, Liao J. 15-Fluoro prostaglandin FP agonists: a new class of topical ocular hypotensives. Biorganic Medicinal Chemistry 12: 3451-3469 (2004).
  147. Sharif NA, Drace CD, Williams GW, Crider JY. Cloned human 5HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. J. Pharmacy & Pharmacology 56: 1267-1274 (2004)
  148. Sharif NA, Williams GW, Crider JY, Xu SX, Davis TL. Molecular pharmacology of the ocular hypotensive DP/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes. J. Ocular Pharmacology & Therapeutics 20: 489-508 (2004).
  149. Sharif NA, Xu SX. Binding affinities of ocular hypotensive -blockers levobetaxolol, levobunolol and timolol at endogenous guinea pig –adrenoceptors. J. Ocular Pharmacology & Therapeutics 20: 93-99 (2004).
  150. Glennon RA, Bondarev ML, Khoran N, Young R, May JA, Hellberg MR, McLaughlin MA, Sharif NA. β-Oxygenated analogues of the 5HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Medicinal Chemistry 47: 6034-6041 (2004).
  151. Patil RV, Sharif NA. Aquaporin channel-mediated water flow: drug discovery opportunities for ocular and otic diseases. Current Topics in Pharmacology 9: 97-106 (2005).
  152. Sharif NA, Davis TL, Williams GW. Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections. J. Ocular Pharmacology & Therapeutics 21: 121-132 (2005).
  153. Sharif NA, Kelly, CR, McLaughlin MA. Human trabecular meshwork cells express functional serotonin-2 (5HT2) receptors: role in IOP reduction. Investigative Ophthalmology & Visual Science. 47: 4001-4010 (2006).
  154. 154. Kelly CR, Sharif NA. Pharmacological evidence for a functional serotonin-2B receptor subtype in a human uterine smooth muscle cell line. J. Pharmacology & Expt. Therapeutics 317: 1254-1261 (2006).
  155. Sharif NA, Crider JY, Kelly CR, Davis TL. Serotonin-2 (5HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. J. Ocular Pharmacology & Therapeutics 22: 389-401 (2006).
  156. Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR. Molecular Vision 12: 1040-1047 (2006).
  157. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA. 1-((S)-2-Aminopropyl)-1H-indazol-6-ol: (AL-34662) A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J. Medicinal Chemistry 49: 318-328 (2006).
  158. Sharif NA, McLaughlin MA, Kelly CR, Xu SX, Crider JY, Parker J. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa-prostaglandin analog. J. Ocular Pharmacology & Therapeutics 22: 291-309 (2006).
  159. Feng Z, Mohapatra S, Klimko PG, Hellberg M, May JA, Kelly CR, Williams GW, McLaughlin MA, Sharif NA. Novel benzodifuran analogs as potent 5HT2A receptor agonists with ocular hypotensive activity. Bioorganic Medicinal Chemistry Letters 17: 2998-3002 (2007).
  160. Sharif NA, Klimko PG. CNS: Ophthalmic Agents, in Comprehensive Medicinal Chemistry II., Vol. 6, Chapter 12, p. 297-320 (Eds: J.B. Taylor & D.J. Triggle), Elsevier, Oxford (2007).
  161. Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J. Ocular Pharmacology & Therapeutics 23: 1-13 (2007).
  162. Camras CB, Sharif NA, Wax MB, Stjernshantz J. Bimatoprost, the prodrug of a prostaglandin analogue. British J. Ophthalmology 92: 862-863 (2008).
  163. Sharif NA. Synthetic FP-class prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins Leukotrienes & Essential Fatty Acids 78: 199-207 (2008).
  164. Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J. Ocular Pharmacology & Therapeutics 24: 152-163 (2008).
  165. Sharif NA, Klimko P. Update and commentary on the prodrug bimatoprost and a putative prostamide receptor. Expert Review Ophthalmology 4: 477-489 (2009).
  166. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan G-L, Camras C. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes. Experimental Eye Research 88: 386-397 (2009).
  167. Feng Z, Hellberg MR, Sharif NA, McLaughlin MA, Williams GW, Scott D, Wallace T. Discovery of 13-oxa prostaglandin analogs as novel antiglaucoma agents: synthesis and biological activity. Bioorganic Medicinal Chemistry 17: 576-584 (2009).
  168. Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel. Invest. Ophthalmology & Visual Science 50: 3353-3359 (2009).
  169. Sharif NA, Hellberg PE, Pang I-H, Gamache DA, Yanni JM. Human conjunctival epithelial cell responses to platelet-activating factor: signal transduction and release of pro-inflammatory cytokines. Molecular Vision 15: 1153-1161 (2009).
  170. May JA, Sharif NA, Chen H-H, Liao JC, Kelly CR, Glennon RA, Young R, Li J-X, Rice KC, France CP. Pharmacological properties and discriminative stimulus effects of a novel and selective 5HT2 receptor agonist, AL-38022A [(S)-2- (8,9- dihydro-7H- pyrano[2,3g]indazol-1-yl)-1-methylethylamine]. Pharmacology, Biochemistry & Behavior 91 : 307-314 (2009).
  171. Dismuke WM, Sharif NA, Ellis DZ. Endogenous regulation of human Schlemm’s canal cell volume by nitric oxide signaling. Invest. Ophthalmology & Visual Science 51: 5817-5824 (2010).
  172. Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular mechanisms of action: novel drug targets for glaucoma treatment. Current Drug Targets 11: 978-993 (2010).
  173. Faulkner R, Sharif NA, Orr S, Craven R, Moster M, Sall K, Whitson J, Bethem R, Curtis M, Dahlin D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN® or TRAVATAN®. J. Ocular Pharmacology & Therapeutics 26: 147-156 (2010).
  174. Dibas A, Oku H, Fukuhara M, Kurimoto T, Ikeda T, Patil RV, Sharif NA, Yorio T. Changes in ocular aquaporins expression following optic nerve crush. Molecular Vision 16: 330-340 (2010).
  175. Sharif NA, Wiernas TK. Platelet-activating factor (PAF)-induced intracellular signaling and release of cytokines and prostaglandin E2 in immortalized human corneal epithelial cells. J. Ocular Pharmacology Ther. 26: 21-29 (2010).
  176. Henderson AJ, Hadden M, Guo C, Douglas N, Decornez H, Hellberg MR, Rusinko A, McLaughlin M, Sharif NA, Drace C, Patil R. 2,3-Diaminopyrines as rho kinase inhibitors. Bioorganic Medicinal Chemistry Letters 20: 1137-1140 (2010).
  177. Katoli P, Sharif NA, Sule A, Dimitrijevich SD. NPR-B natriuretic peptide receptors in human corneal epithelium: mRNA, immunohistochemical, protein and biochemical pharmacology studies. Molecular Vision 16: 1241-1252 (2010).
  178. Sharif NA, Crider JY. Human choroidal melanocytes signal transduction responses to various pharmacological agents: focus on endothelin. Current Eye Research 36: 462-468 (2011).
  179. Sharif NA, May JA. Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5HT2 receptor agonists. Expert Reviews Ophthalmology 6: 105-120 (2011).
  180. Ramachandran C, Patil RV, Sharif NA, Srinivas SP. Effect of elevated intracellular cAMP on actomyosin contraction in bovine trabecular meshwork cells. Investigative Ophthalmology & Visual Science 52: 1474-1485 (2011).
  181. Sharif NA, Crider JY. Intracellular signaling in human iridial fibroblasts and iridial melanocytes in response to prostaglandins, endothelin, isoproterenol and other pharmacological agents. Current Eye Research 36: 310-320 (2011).
  182. Ramachandran C, Patil RV, Combrink K, Sharif NA, Srinivas SP. Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Molecular Vision 17: 1877-1890 (2011).
  183. Sharif NA. Ocular hypotension: involvement of serotonergic 5HT2 receptors. Chapter 26, in: The pathophysiology of central 5HT2C receptors”. (Di Giovanni, G, Esposito, E & Di Matteo, V, Eds), Humana Press, Springer Publishing Company, New York, NY. (2011).
  184. Sharif NA, Xu S, Li L, Katoli P, Kelly CR, Wang Y, Cao S, Patil R, Husain S, Klekar L, Scott D. Protein expression, biochemical pharmacology of signal transduction, and relation to IOP modulation by bradykinin B2-receptors in ciliary muscle. Molecular Vision 19: 1356-1370 (2013).
  185. Sharif NA, Katoli P, Scott D, Li L, Kelly CR, Xu S, Husain S, Toris C, Crosson C. FR-190997, [AL-44205], a non-peptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys. Drug Development Research 75: 211-223 (2014).
  186. Sharif NA, Wang Y, Katoli P, Xu S, Kelly CR, Li L. Human non-pigmented ciliary epithelium bradykinin B2-receptors: receptor localization, pharmacological characterization of intracellular Ca2+ mobilization, and prostaglandin secretion. Current Eye Research 39: 378-389 (2014).
  187. Chen H-H, Namil A, Severns B, Ward J, Kelly CR, Drace C, McLaughlin MA, Yacoub S, Li B, Patil R, Sharif NA, Hellberg MR, Rusinko A, Pang I-H, Combrink KD. In Vivo optimization of 2,3-diaminopyrazine Rho kinase inhibitors. Bioorganic Medicinal Chemistry Letters 24: 1875-1879 (2014).
  188. Sharif NA, Katoli P, Kelly CR, Li L, Xu S, Wang Y, Klekar L, Earnest D, Yacoub S, Hamilton G, Jacobson N, Shepard AR, Ellis D. Trabecular meshwork bradykinin receptors: mRNA levels, immunohistochemical visualization, signaling processes pharmacology and linkage to IOP changes. J. Ocular Pharmacology & Therapeutics 30: 21-34 (2014).
  189. Sharif NA, Li L, Katoli P, Xu S, Veltman J, Li B, Scott D, Wax M, Gallar J, Acosta C, Belmonte C. Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule. Experimental Eye Research 128: 170-180 (2014).
  190. May JA, Sharif NA, McLaughlin MA, Chen H-H, Severns BS, Kelly CR, Holt WF, Young R, Glennon RA, Hellberg, MR, Dean TR. Ocular hypotensive response in non-human primates of (R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol [AL-37807] a selective 5-HT2 receptor agonist. J. Medicinal Chemistry 58 : 8818-8833 (2015).
  191. Sharif NA, Klekar L, Li L, Xu S. Ocular hypotensive activity of a non-peptide bradykinin B2-receptor antagonist (WIN-64338) in Dutch-Belt rabbits: a case of poly-pharmacology in action. Int. J. Ophthalmology & Clinical Research 2.3 [8 pages] (2015).
  192. Sharif NA. Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes. J. Ocular Pharmacology & Therapeutics 31: 131-145 (2015).
  193. Patil R, Xu S, Rusinko A, Feng Z, Katoli P, May JA, Hellberg M, Sharif NA, Wax M, Irigoyen M, Clarke M, Bordeau B, McGraith S, Luche M, van Hoek A, Brittain T, Brown P, Colbert D, Kumari SS, Varadaraj K, Mitra AK, Carr G. Rapid identification of novel inhibitors of aquaporin-1 channel by high-throughput screening. Chemical Biology & Drug Design 87: 794-805 (2016).
  194. Sharif NA, Patil R, Li L, Husain S. Human ciliary muscle cell responses to kinins: activation of ERK1/2 and pro-matrix metalloproteinases secretion. World J. Ophthalmology 6: 20-27 (2016).
  195. Sharif NA. Ocular hypertension and glaucoma: a review and current perspectives. Int. J. Ophthalmology & Visual Science. 2 (3): 22-36 (2017).
  196. Patil R, Wang H, Sharif NA, Mitra A. Aquaporins: novel targets for age-related ocular disorders. J. Ocular Pharmacology & Therapeutics (submitted).
  197. Sharif NA. Prospects of treating ocular hypertension and glaucoma with peptidic and non-peptide kinin mimetic drugs. JOJ Ophthalmology (submitted)
  198. Sharif NA. idrug and idevices discovery and development- preclinical studies for ocular hypotensives and neuroprotectants. J. Ocular Pharmacology Therapeutics (in prep).
  199. Klimko P, Sharif NA. FP prostanoid receptor antagonists: medicinal chemistry and pharmacology. Brit. J Pharmacology (in prep).
  200. Sharif NA. Ocular bradykinin receptors: localization, signal transduction, pharmacology and drug development aspects. Experimental Eye Research (in prep).
  201. Sharif NA. Prostanoid receptors in the eye: distribution, signaling and drugs to treat ocular diseases. Med. Hypothesis, Discovery & Innovation Ophthalmology (in prep).
  202. Chen H-H, Namil A, Severns B, Kelly CR, Drace C, McLaughlin MA, Xu S, Li L, Patil R, Sharif NA, Hellberg MR, Rusinko A, Pang I-H, Prasanna G, Combrink KD. Non-peptide bradykinin agonists for the treatment of glaucoma. Bioorganic Medicinal Chemistry Letters (in prep).

cancer-research Journal Flyer